Drug Profile
Danicamtiv - MyoKardia
Alternative Names: BMS-986434; MYK 491; SAR 440181Latest Information Update: 19 Apr 2024
Price :
$50
*
At a glance
- Originator MyoKardia
- Developer MyoKardia; Sanofi
- Class Amides; Cardiovascular therapies; Fluorinated hydrocarbons; Isoxazoles; Organic sulfur compounds; Piperidines; Pyrazoles; Small molecules
- Mechanism of Action Cardiac myosin stimulants; Genetic process modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Dilated cardiomyopathy
Most Recent Events
- 19 Mar 2024 Bristol-Myers Squibb completes a pharmacokinetics phase-I trial in Heart Failure in USA (NCT05952089)
- 22 Feb 2024 Bristol-Myers Squibb terminates phase-II trial in Dilated Cardiomyopathy in USA, Spain, Germany and United Kingdom (PO) (NCT04572893)
- 10 Nov 2023 Bristol-Myers Squibb completes the phase I pharmacokinetics trial (In Volunteers) in USA (NCT06027437)